Pluribus Labs’s Adtran ADTN Stock Holding History

Pluribus Labs’s Portfolio ADTN Stock Details ADTN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,751	Closed	-$360K	–	51
2021 Q4	$360K	Buy	+15,751	New	+$319K	0.38%	99

Other funds holding ADTN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCA

Bernzott Capital Advisors Camarillo, California $209M AUM 9.57% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Pluribus Labs's ADTN Position: Q1 2022 in Review

Pluribus Labs sold out of Adtran (ADTN) in Q1 2022, closing a stake of 15,751 shares — an estimated $360K sold.

Pluribus Labs first reported a position in ADTN in Q4 2021 and held it in 1 quarter. The position peaked at $360K in Q4 2021. 187 funds tracked by Wall St. Rank hold ADTN as of Q1 2022.

Pluribus Labs reported no remaining Adtran position as of Q1 2022 after selling out during the quarter.
Pluribus Labs sold 15,751 Adtran shares in Q1 2022, an estimated $360K.
Pluribus Labs first reported a position in Adtran in Q4 2021 and held it in 1 quarter.
Pluribus Labs's Adtran position peaked at $360K in Q4 2021.
187 funds tracked by Wall St. Rank held Adtran as of Q1 2022.

Based on Pluribus Labs's 13F filing for Q1 2022, filed 16 May 2022.